Skip to content
Menu Close
Close button
Go back to News

Former Voyager CEO Andre Turenne makes a comeback with Atlas-backed covalent drug biotech 

In February, Endpoints News reported that Turenne had signed on to head a stealth mode Atlas Venture-backed biotech EoCys. After a name change in March, EoCys has evolved into Matchpoint Therapeutics, which is coming out of stealth with a $70 million Series A and a focus on making covalent drugs, or drugs that bind irreversibly.